| Outcome Measures: |
Primary: Part A: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration, A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module, Baseline up to Week 16|Part B: Change from Baseline in Total Clamp Disposition Index (cDI), Change from Baseline in Total cDI, Baseline up to Week 12 | Secondary: Part A: Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3532226, PK: Cmax of LY3532226, Predose on Day 1 through Week 16|Part A: PK: Area Under the Concentration Versus Time Curve (AUC) of LY3532226, PK: AUC of LY3532226, Predose on Day 1 through Week 16|Part B: Change from Baseline in Insulin Secretion Rate (ISR) from hyperglycaemic clamp, Change from Baseline in ISR from hyperglycaemic clamp, Baseline through Week 12|Part B: Change from Baseline in β-cell Glucose Sensitivity (GS) from hyperglycaemic clamp, Change from Baseline in β-cell GS from hyperglycaemic clamp, Baseline through Week 12|Part B: Change from Baseline in Hyperinsulinemic Euglycemic Clamp M-value, Change from Baseline in Hyperinsulinemic Euglycemic Clamp M-value, Baseline through Week 12|Part A & B: Change from Baseline in Fasting and Post meal Glucose during Standardized Mixed-meal Tolerance Test (sMMTT), Change from Baseline in Fasting and Post meal Glucose during sMMTT, Baseline through Week 16|Part A & B: Change from Baseline in Glycosylated Haemoglobin (HbA1c), Change from Baseline in HbA1c, Baseline through Week 16|Part A & B: Change from Baseline in Glucagon Concentration at Fasting and Post meal during sMMTT, Change from Baseline in Glucagon Concentration at Fasting and Post meal during sMMTT, Baseline through Week 16
|
